Navigation Links
APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
Date:9/3/2007

ARLINGTON, Va., Aug. 22 /PRNewswire-USNewswire/ -- The American Psychiatric Association (APA) applauds the U.S. Food and Drug Administration (FDA) for its review of scientific evidence that led to the approval of a new treatment for two severe psychiatric disorders in children. The APA is pleased that the approvals are a result of the federal Best Pharmaceuticals for Children Act (BCPA), which was designed to encourage research that leads to this kind of approval, given that dosages, side effects and efficacy can vary significantly with children.

"Schizophrenia and bipolar disorder are severely disabling to patients and devastating to their families," said APA President Carolyn Robinowitz, M.D. "For many children suffering with psychiatric illnesses, medications are an important part of a comprehensive treatment program, which should include talk therapy and other interventions."

"For any medication there are benefits and potential risks," said Darrel Regier, M.D., M.P.H., director, APA Division of Research, and executive director, American Psychiatric Institute for Research and Education. "For many children with these disorders, the FDA's action today provides additional information to guide treatment options in these special populations. We anticipate that approval of this medication will encourage federal research agencies to accelerate urgently needed studies of mental disorders in children."

Physicians and parents must work together to evaluate the risks and benefits of any particular treatment. The APA recommends that all treatment for psychiatric illnesses are guided by a thorough evaluation and careful diagnosis, followed up with a treatment plan tailored to the needs of the child and the family.

About the American Psychiatric Association:

The American Psychiatric Association is a national medical specialty society whose more than 38,000 physician members specialize in diagnosis, treatment, prevention and research of mental illnesses including substance use disorders. Visit the APA at http://www.psych.org and http://www.HealthyMinds.org.

For Information Contact:

Lydia Sermons-Ward, 703-907-8640

press@psych.org

Alissa Schulman, 703-907-8562

aschulman@psych.org


'/>"/>
SOURCE American Psychiatric Association
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Northfield Labs Receives FDA Comments
2. FDAs Failure Urges It to Reassess Its Policies
3. FDAs Gesture for Firm Manufacturing Drug for Cushings Syndrome
4. First Vaccine Designed for Africa Cleared for Testing in Humans
5. Infant receives first bloodless liver transplant
6. Oracle Corp. to help build worlds first "Digital Hospital"
7. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
8. First human clone is near
9. First Artificial Heart patient has Major setback
10. First global SARS meet opens
11. Launch Of India’s First Virology Course At Pun
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... Plastic Surgery Associates is ... Top Doctor for 2017. Each year, research and information firm, Castle Connolly, releases their ... title in 2015, this marks the 3rd time that Dr. Canales has ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... grant from the American Heart Association (AHA) to launch a Rheumatic Heart Disease ... the prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged ...
(Date:6/22/2017)... ... June 22, 2017 , ... Vighter, a premier ... received certification for ANSI/ASIS PSC.1-2012. The company’s work in countries throughout Southwest Asia, ... of law has been degraded. The PSC.1 standard was created to protect fundamental ...
(Date:6/20/2017)... Tennessee (PRWEB) , ... June 20, 2017 , ... ... care services, announced today that Claritas Capital, a Nashville-based private equity firm, has ... accelerate our expansion plans for some time, and Claritas Capital offers the smart ...
(Date:6/20/2017)... ... 2017 , ... After months of negotiations, FaceCradle USA is proud to announce the debut of ... , “Introducing our product on QVC is something we all worked hard to achieve for ... more than 90 million homes in the United States,” said FaceCradle USA President Dylan Doherty. ...
Breaking Medicine News(10 mins):
(Date:5/29/2017)... 2017  Cellect Biotechnology Ltd. (NASDAQ: APOP ... the functional selection of stem cells, today provided a ... quarter ended March 31 st , 2017. ... the first quarter of 2017," said Dr. Shai Yarkoni, ... the treatment of the first blood cancer patient in ...
(Date:5/24/2017)... 24, 2017  ivWatch LLC today announced the ... Board to enable seamless integration of ivWatch,s groundbreaking ... infusion pumps and other devices. By integrating ivWatch ... to help health care customers deliver a higher ... to IV therapy. "The ivWatch OEM ...
(Date:5/22/2017)... , May 22, 2017  As the ... a whole continue to make the revolutionary shift ... increasingly important for ensuring positive patient outcomes and ... stakeholders are shifting focus away from clinical trials ... effects of long-term specialty drug therapy utilization in ...
Breaking Medicine Technology: